Identification of HER2 expression or amplification by liquid biopsy demonstrated the clinical benefits of trastuzumab treatment in patients with GC whose CTCs or cfDNA showed HER2 expression or amplification, respectively, although their primary tumors were histologically HER2 negative34,45. Here, ERBB2 is linked to gastric cancer.